Infraredx, a Nipro Company, is a pioneer in intravascular imaging for mapping coronary artery disease. In addition to our IVUS+NIRS intravascular imaging technology, the NIPRO Company brings a complete portfolio of diverse and innovative interventional cardiology and peripheral vascular solutions, including FFR, PTCA & PTA balloons, and other accessories.
Founded in 1954, Nipro is a publicly-traded (Token SE) company with revenue of $3.25 billion and an operating income of more than $260 million. Nipro Corporation offers products and technologies that meet the needs of patients and medical professionals in a wide range of fields, such as artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, ethical pharmaceuticals, and medical glass products. The agreement combines the strengths of Nipro Corporation and Infraredx, by leveraging Nipro’s strong global cardiovascular portfolio and resources along with Infraredx’s industry expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS). The agreement will help introduce Nipro’s cardiovascular product line into the United States, and continue Infraredx’s mission to empower interventional cardiologists with the advanced imaging tools required to predict heart attacks and prevent them—catalyzing a global shift from reactive treatment to proactive care of coronary artery disease.
Click the button to learn more about the Nipro product portfolio.Learn More
© 2020 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative